1.Microalbuminuria in non-diabetic patients with cerebral infacrtion.
Hyung Chul KIM ; Woon San KO ; Im Seok KOH ; Hong Ki SONG ; Byung Chul LEE
Journal of the Korean Neurological Association 1999;17(2):206-210
BACKGROUND: Microalbuminuria predicts cardiovascular events in diabetic and non-diabetic patients. But, few studies have addressed the relationship between microalbuminuria and cerebral infarction. We determined the incidence of microalbuminuria in non-diabetic subjects with cerebral infarction and investigated the relationship between urinary albumin excretion and risk factors of the stroke. METHODS: Urinary albumin excretion rate, 24 hours blood pressure monitoring, fasting serum lipid profiles, fibrinogen, fasting glucose, insulin and c-peptide were evaluated in 50 non-diabetic patients with acute cerebral infarction and matched 48 controls. RESULTS: Microalbuminuria was detected in 23 of 50(46%) patients with acute cerebral infarction and 4 of 48(8%) control subjects. Hypertension was present in 13 of 23(57%) microalbuminuric patients and 9 of 27(33%) non-microalbuminuric patients. In the microalbuminuric patients with cerebral infarction, diastolic blood pressure and fasting glucose were significantly greater than the control group. But, no difference in systolic blood pressure, lipid level, fibrinogen, fasting insulin and c-peptide level. CONCLUSIONS: The prevalence of microalbuminuria in patients with cerebral infarction was higher than controls and it was associated with increased diastolic blood pressure(DBP) and fasting blood glucose(FBS). Therefore, microalbuminuria is associated with thrombogenic cerebral infarction and it was partly mediated by DBP and FBS.
Blood Pressure
;
Blood Pressure Monitors
;
C-Peptide
;
Cerebral Infarction
;
Fasting
;
Fibrinogen
;
Glucose
;
Humans
;
Hypertension
;
Incidence
;
Insulin
;
Prevalence
;
Risk Factors
;
Stroke
2.MR Imagings of Chronic Acquired Hepatic Failure.
Kyung Soo KANG ; Sang Yun KIM ; Sung Hee HWANG ; Woon San KO ; Hyeon Mi LEE ; Ki Han KWON ; Byung Chyul LEE
Journal of the Korean Neurological Association 1995;13(1):84-90
Neuroimaging of the brain is useful diagnostic evaluation of patients with hepatic encephalopathy msofar as it is able to exclude other causes of abno rmal mental status. Recently, changes of basal ganglia on MRI characteriwd by increased signal mtensity on Tl-weighted images were reported m patients with liver cirrhosis. Signal abnormality involves mainly the globus pallidus and seems to be specific for patients with chronic liver disease. Its pathogenesis and significance are obscure, and no pathological reports have been made. We experienced 3 cases of Chronic acquired hepatic failure whose MRI showed increased signal in-tensity in the basal ganglia on Tl-weighted imaging. Our findings su-ggest that basal ganglia signal abnormality could arise as a marker of brain impairment related to deposition of an unidentified paramagnetic substance or altered intracellular water relaxation.
Basal Ganglia
;
Brain
;
Globus Pallidus
;
Hepatic Encephalopathy
;
Humans
;
Liver Cirrhosis
;
Liver Diseases
;
Liver Failure*
;
Magnetic Resonance Imaging
;
Neuroimaging
;
Relaxation
3.The Usefulness of 18 F-FDG PET to Differentiate Subtypes of Dementia:The Systematic Review and Meta-Analysis
Seunghee NA ; Dong Woo KANG ; Geon Ha KIM ; Ko Woon KIM ; Yeshin KIM ; Hee-Jin KIM ; Kee Hyung PARK ; Young Ho PARK ; Gihwan BYEON ; Jeewon SUH ; Joon Hyun SHIN ; YongSoo SHIM ; YoungSoon YANG ; Yoo Hyun UM ; Seong-il OH ; Sheng-Min WANG ; Bora YOON ; Hai-Jeon YOON ; Sun Min LEE ; Juyoun LEE ; Jin San LEE ; Hak Young RHEE ; Jae-Sung LIM ; Young Hee JUNG ; Juhee CHIN ; Yun Jeong HONG ; Hyemin JANG ; Hongyoon CHOI ; Miyoung CHOI ; Jae-Won JANG ; On behalf of Korean Dementia Association
Dementia and Neurocognitive Disorders 2024;23(1):54-66
Background:
and Purpose: Dementia subtypes, including Alzheimer’s dementia (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), pose diagnostic challenges. This review examines the effectiveness of 18 F-Fluorodeoxyglucose Positron Emission Tomography ( 18 F-FDG PET) in differentiating these subtypes for precise treatment and management.
Methods:
A systematic review following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines was conducted using databases like PubMed and Embase to identify studies on the diagnostic utility of 18 F-FDG PET in dementia. The search included studies up to November 16, 2022, focusing on peer-reviewed journals and applying the goldstandard clinical diagnosis for dementia subtypes.
Results:
From 12,815 articles, 14 were selected for final analysis. For AD versus FTD, the sensitivity was 0.96 (95% confidence interval [CI], 0.88–0.98) and specificity was 0.84 (95% CI, 0.70–0.92). In the case of AD versus DLB, 18F-FDG PET showed a sensitivity of 0.93 (95% CI 0.88-0.98) and specificity of 0.92 (95% CI, 0.70–0.92). Lastly, when differentiating AD from non-AD dementias, the sensitivity was 0.86 (95% CI, 0.80–0.91) and the specificity was 0.88 (95% CI, 0.80–0.91). The studies mostly used case-control designs with visual and quantitative assessments.
Conclusions
18 F-FDG PET exhibits high sensitivity and specificity in differentiating dementia subtypes, particularly AD, FTD, and DLB. This method, while not a standalone diagnostic tool, significantly enhances diagnostic accuracy in uncertain cases, complementing clinical assessments and structural imaging.